Pelthos Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Pelthos Therapeutics Inc. (PTHS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.00 per share for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2025-08-13
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $7.50.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $7.50, a 66.93% decline from fiscal 2023.
- Pelthos Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $22.68.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | $7.50 10-K · filed 2025-03-27 | ||||
| 2024-09-30 | $7.50 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $75.00 10-Q · filed 2025-08-13 | $7.50 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $7.50 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | $22.68 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |